Epithelial ovarian cancer Trials in Seoul, South Korea
Conditions / Epithelial ovarian cancer / Seoul, South Korea
Epithelial ovarian cancer is a medical condition with active clinical research programs worldwide.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial | COMPLETED | PHASE2/PHASE3 |
| NCT03522246 | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | COMPLETED | PHASE1 |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | RECRUITING | PHASE3 |
| NCT04516447 | A Study of ZN-c3 in Patients With Ovarian Cancer | RECRUITING | PHASE1 |
| NCT02859038 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRĪ±) Expression | COMPLETED | PHASE3 |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | RECRUITING | PHASE2 |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | TERMINATED | PHASE2/PHASE3 |